CommercialPrior AuthMedium impact
Soriatane (acitretin)
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Family Medicine, Internal Medicine·Medical Policy
Effective date
Mar 20, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their Soriatane (acitretin) policy for severe psoriasis treatment, maintaining prior authorization requirements with specific criteria including age ≥18, confirmed diagnosis, pregnancy restrictions for females, and documented failure of at least one alternative therapy. The policy was reviewed and approved by P&T Committee on 03/20/2025 with 12-month approval periods.
Action Required
Immediately: Billing team must ensure prior authorization is obtained for all Soriatane (acitretin) prescriptions for BCBS Mississippi members. Verify patients meet ALL criteria: age ≥18, confirmed moderate to severe psoriasis diagnosis, not pregnant (if female), and documented failure of one alternative therapy (PUVA, methotrexate, cyclosporine, or two topical corticosteroids). Update system to flag this medication for PA requirement. Claims will be denied without proper prior authorization.